Note: This section contains information in English only.Shares in Novo Nordisk plunged nearly 8% to close at 260 Danish kroner on Monday, hitting their lowest level since April after the Danish drugmaker's capital markets day presentation failed to reassure investors over its mid-term growth outlook. Despite showcasing positive Phase 3 trial data for its next-generation obesity and diabetes treatment Cagrisema, which achieved greater weight loss than Eli Lilly's Zepbound, investors reacted negatively to conservative 2030 operating margin guidance and a lack of granular turnaround plans as the company faces impending patent expiries for Ozempic and Wegovy.
Tue, 22 Sep 2026 07:07:26 GMT
Source: Dukascopy Bank SA